We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 746

As Congress Struggles With ACA Repeal, Trump Administration Moves Forward With Regulatory Reform
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • January 23 2018

The Trump administration and Republican-led Congress spent substantial time and political capital in 2017 on efforts to repeal and replace the


The Internet of Pills: The FDA’s Approval of Digital Smart Pills Takes the Internet of Things to New Levels
  • Gordon Rees Scully Mansukhani
  • USA
  • November 15 2017

If your insurance company knew that you did not take your medication as prescribed, could it deny future coverage? Could your physician refuse to


Practical Considerations for Device Industry Policyholders Experiencing Puerto Rico Hurricane Losses
  • Covington & Burling LLP
  • USA
  • October 25 2017

Last week, FDA released a statement about the challenges facing the medical device manufacturing industry in Puerto Rico in the wake of Hurricanes


Behind the War Between Health Insurers and Pharmacy Benefit Managers
  • Buchalter
  • USA
  • May 26 2017

Pharmacy benefit managers and health insurance companies, in theory, should be close partners. But Anthem’s protracted litigation with its PBM


The Rescission Trap: Don't Let Product Recalls Contaminate Your Coverage
  • Hunton & Williams LLP
  • USA
  • April 10 2017

Product recalls are on the rise in many industries. The year 2016 saw over 8,000 products recalled by the Food and Drug Administration and nearly 15


Myths & Misconceptions of Biotech Securities Claims: An Analysis of Motion to Dismiss Results from 2005-2016
  • Lane Powell PC
  • USA
  • March 15 2017

Small, development stage biotech companies are widely considered to be attractive targets for securities actions given the


Total Recall: Maximizing the Return on Product RecallContamination Insurance
  • Pillsbury Winthrop Shaw Pittman LLP
  • USA
  • October 10 2016

If you believe the news, I may be lucky to make it out of the driveway alive on my morning commute tomorrow. That microwave-ready triple egg breakfast


The Marijuana Industry’s Big Win: The DEA’s Refusal to Reschedule
  • Wilson Elser
  • USA
  • August 23 2016

Earlier this year, when the U.S. Drug Enforcement Agency (DEA) indicated it would have an announcement regarding a now five-year-old petition to


Contractual Liability Exclusion Not a Basis to Deny Coverage for Consumer Claims Against Genetic Testing Company
  • Gordon Rees Scully Mansukhani
  • USA
  • August 4 2016

The Federal District Court in San Jose, California, issued a recent decision interpreting a contractual liability exclusion issued by IronShore to


Digital Health Law Update, Vol. II, Issue 3
  • Jones Day
  • USA
  • June 15 2016

The U.S. Senate Committee for Health, Education, Labor and Pensions, known as HELP, recently passed its marked version of the Medical Electronic Data